A new scientific statement from the American Heart Association cautions that cuffless blood pressure monitoring devices, while promising, lack the validation necessary for clinical use in diagnosing or treating hypertension. Published in the Association's journal Hypertension, the statement aligns with the recent 2025 AHA/ACC High Blood Pressure Guideline, which recommends against using these devices for medical decision-making until they demonstrate greater precision.
The proliferation of smartwatches, rings, patches, and fingertip monitors over the past decade has created a market of convenient, continuous monitoring tools. However, the statement notes that the speed of commercialization has outpaced the science. Many personal wearable devices have not been proven accurate or reliable for real-world conditions such as during exercise, sleep, daily activity, or after taking medication that affects blood pressure. Variables like arm position, skin color, and calibration timing can also contribute to inaccurate measurements.
"Cuffless blood pressure devices are easy to use, convenient and capable of frequent or continuous monitoring, potentially providing insights into blood pressure changes during daily life and sleep," said statement writing group chair Jordana Cohen, M.D., M.S.C.E., FAHA. "However, without proper validation, readings from cuffless blood pressure devices are not reliable sources to inform treatment decisions or evaluate interventions." The statement emphasizes that incorrect data could lead to false reassurance, unnecessary alarm, or inappropriate medication adjustments.
The technologies operate using methods like photoplethysmography or tonometry and may require calibration with a traditional arm cuff. While some devices have received FDA clearance, the statement highlights that such clearance does not require formal accuracy testing under a standardized protocol. Up to 80% of all blood pressure devices sold globally have never undergone formal validation testing, with cuffless devices showing even lower rates.
For business and technology leaders, the implications are significant. The wearable health technology market faces a critical validation gap that must be addressed before these devices can transform care. The statement calls for standardized validation protocols that reflect real-world use, research to correlate device readings with cardiovascular outcomes, and greater transparency from manufacturers regarding algorithms and data privacy.
If accuracy and reliability issues are resolved, cuffless technologies could expand hypertension screening and management, particularly in under-resourced communities. The statement notes that developers must prioritize addressing potential inaccuracies related to skin color, as well as issues of connectivity and affordability. A list of validated blood pressure devices is available at validatebp.org.
For now, the American Heart Association advises that patients using these devices inform their doctors that readings come from cuffless technology and discuss using a validated device for any measurements used in hypertension diagnosis or treatment management. The statement concludes that clear standards and coordinated efforts in research, regulation, and public education are essential to ensure that innovation enhances, rather than compromises, cardiovascular care for the estimated 1.4 billion adults affected globally.
